India seeks US intervention in Ranbaxy fraud trial
This article was originally published in Scrip
Executive Summary
India is seeking the intervention of the US government in theRanbaxy case, where the company is being investigated for submitting allegedly fabricated data for its generics to theFDA, among other charges.
You may also be interested in...
Novartis Sheds Vildagliptin Trademark In India Ahead Of Patent Expiry
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla's COO Steps Down
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.
Newbie Remogliflozin Gives Competition A Run For Their Money
Remogliflozin prescriptions gallop in India and Glenmark expects the ‘affordable’ therapy to take share from other SGLT2 inhibitors.
Need a specific report? 1000+ reports available
Buy Reports